<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
June 22, 2000
----------------------------------------
(Report Date of Earliest Event Reported)
Millennium Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Exact name of Registrant as Specified in its Charter)
DELAWARE 0-28494 04-3177038
---------------------------- ----------- -------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
75 Sidney Street, Cambridge, Massachusetts 02139
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) Zip Code)
Registrant's telephone number, including area code: (617) 679-7000
--------------------------------------------------------------------------------
(Former Name or Former Address if Changed Since Last Report)
<PAGE>
ITEM 5: OTHER EVENTS
On June 23, 2000, Millennium Pharmaceuticals, Inc. (the "Company")
issued a press release to announce that it had entered into an alliance with
Aventis Pharma, the pharmaceutical company of Aventis S.A., covering the
development and commercialization of drugs for the treatment of inflammatory
diseases; the joint development of new drug discovery technologies; the
transfer of key elements of the Company's technology platform to Aventis; and
the purchase of an equity interest in the Company by Aventis. A copy of the
press release is attached to this current Report on Form 8-K as Exhibit 99.1.
The closing of the alliance will be subject to expiration or early
termination of the applicable waiting period under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: June 30, 2000 MILLENNIUM PHARMACEUTICALS, INC.
/s/ John B. Douglas III
--------------------------------
John B. Douglas III
General Counsel
2
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT NUMBER DESCRIPTION
-------------- -----------
<S> <C>
99.1 Press Release dated June 23, 2000
</TABLE>
3
